Compare Vanguard Mega Cap Growth ETF (MGK) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Mega Cap Growth ETF trades at $90.18, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| MGK | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $92.06 | $164.28 |
52-Week Low | $70.70 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK trades at $90.21, down 0.46% on the day, with a bullish technical signal supported by moving averages. The ETF focuses on mega-cap growth stocks with heavy technology concentration and a low 0.05% expense ratio. Recent news highlights institutional buying activity and strong five-year performance compared to peers.
Outlook remains positive given MGK's track record of outperforming the S&P 500, though high RSI readings suggest potential near-term consolidation. Risks include concentration in tech stocks and market volatility, but the ETF's low-cost structure and exposure to market leaders provide long-term growth potential.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
